

Three New Megastigmane Glucopyranosides from the *Cardamine komarovii*

Il Kyun LEE,^a Ki Hyun KIM,^a Seung Young LEE,^a Sang Un CHOI,^b and Kang Ro LEE^{*,a}

^aNatural Products Laboratory, School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Korea; and ^bKorea Research Institute of Chemical Technology, Teajeon 305-600, Korea.

Received January 25, 2011; accepted March 24, 2011

Three new megastigmane glucopyranosides, komaroveside A [(3*S*,4*R*,5*Z*,7*E*)-3,4-dihydroxy-5,7-megastigmadien-9-one-3-*O*-β-D-glucopyranoside] (**1**), komaroveside B [(3*S*,4*S*,5*S*,6*R*,7*E*)-5,6-epoxy-3,4-dihydroxy-7-megastigmen-9-one-3-*O*-β-D-glucopyranoside] (**2**) and komaroveside C [(3*S*,4*S*,5*S*,6*R*,7*E*,9*S*)-5,6-epoxy-3,4,9-trihydroxy-7-megastigmen-3-*O*-β-D-glucopyranoside] (**3**) were isolated, together with eight known compounds, from *Cardamine komarovii*. The identification of these compounds and the elucidation of their structures were based on 1D- and 2D-NMR spectral data analysis. The isolated compounds were tested for their cytotoxicity against four human tumor cell lines (A549, SK-OV-3, SK-MEL-2, HCT15) *in vitro* using the sulforhodamine B bioassay.

Key words Cruciferae; megastigmane; komaroveside; cytotoxicity; *Cardamine komarovii*

Cardamine komarovii (NAKAI) is a plant that is widely distributed throughout Korea. In Korea, the aerial parts of *C. komarovii* are considered edible.¹⁾ This indigenous herb is used in Chinese medicine as a treatment of hemostasis, depressed blood pressure, and sedation.²⁾ Phytochemical studies of this plant have not yet been reported in the literature. Thus, we investigated the aerial part of *C. komarovii* as a part of our continuous study of the family of Cruciferae. Column chromatography based purification of CHCl₃ and *n*-BuOH-soluble fractions of the MeOH extract of this plant led to the isolation of three megastigmane glucopyranosides (**1**–**3**), together with eight known megastigmane compounds (**4**–**11**). The structures of the known compounds were determined to be (6*R*,9*S*)-3-oxo-α-ionol-9-*O*-β-D-glucopyranoside (**4**),³⁾ (6*S*,9*S*)-roseoside (**5**),⁴⁾ sammangaoside A (**6**),⁵⁾ corchoionoside A (**7**),⁶⁾ icarisode B₂ (**8**),⁷⁾ (3*S*,5*R*,6*R*,7*E*,9*S*)-megastigman-7-ene-3,5,6,9-tetrol-3-*O*-β-D-glucopyranoside (**9**),⁸⁾ staphylionoside E (**10**),⁹⁾ and annuonene D (**11**)¹⁰⁾ by comparing their spectroscopic data with data in the literature

(Fig 1).

Results and Discussion

Komaroveside A (**1**), was obtained as a colorless gum. The molecular formula of **1** was deduced to be C₁₉H₃₀O₈ by positive mode high resolution electrospray ionization mass spectrometry (HR-ESI-MS) data at *m/z* 409.1831 [M+Na]⁺ (Calcd for C₁₉H₃₀O₈Na: 409.1838). The IR spectrum of **1** showed absorption bands at 3382 and 1660 cm⁻¹ ascribable to hydroxyl and ketone functions, respectively. The ¹H-NMR spectrum (Table 1) of **1** displayed signals for four methyl groups at δ_H 2.31, 1.88, 1.14 and 1.09, two oxymethine proton signals at δ_H 4.11 (d, *J*=3.5 Hz) and 4.01 (dt, *J*=12.3, 3.5 Hz) and one methylene proton signals at δ_H 1.92 (br t, *J*=12.3 Hz) and 1.64 (dd, *J*=12.3, 3.5 Hz), and a disubstituted *trans* double bond at δ_H 7.26 (d, *J*=16.4 Hz) and 6.14 (d, *J*=16.4 Hz). In the ¹³C-NMR spectrum, 13 carbon signals appeared besides those of the sugar unit, which included one carbonyl carbon at δ_C 199.5, four methyl carbons at δ_C 28.8,




Fig. 1. The Structures of the Isolated Compounds **1**–**11** from *C. komarovii*

* To whom correspondence should be addressed. e-mail: krlee@skku.ac.kr

Table 1. ^1H - ^{13}C -NMR Data of **1**, **2** and **3**

Position	1^{a)}		2^{a)}		3^{a)}	
	δ_{H}	δ_{C}	δ_{H}	δ_{C}	δ_{H}	δ_{C}
1		36.5		34.1		34.2
2 α	1.64 (dd, 12.3, 3.5)	38.7	1.40 (dd, 12.5, 3.5)	37.2	1.35 (dd, 12.8, 3.5)	37.7
2 β	1.92 (brt, 12.3)		1.84 (brt, 12.5)		1.76 (brt, 12.8)	
3	4.01 (dt, 12.3, 3.5)	74.3	3.97 (dt, 12.5, 3.5)	73.8	3.97 (dt, 12.8, 3.5)	74.2
4	4.11 (d, 3.5)	68.6	4.13 (d, 3.5)	69.2	4.12 (d, 3.5)	69.8
5		131.0		68.7		68.2
6		139.9		70.1		70.4
7	7.26 (d, 16.4)	142.8	7.11 (d, 15.8)	143.4	5.90 (d, 15.8)	124.8
8	6.14 (d, 16.4)	133.3	6.17 (d, 15.8)	132.6	5.66 (dd, 15.8, 6.1)	138.2
9		199.5		198.7	4.29 (dq, 6.8, 6.1, 1.0)	67.4
10	2.31 (s)	26.4	2.29 (s)	26.0	1.22 (d, 6.7)	22.6
11	1.09 (s)	25.8	0.99 (s)	23.6	0.96 (s)	28.4
12	1.14 (s)	28.8	1.18 (s)	28.0	1.09 (s)	23.7
13	1.88 (s)	18.7	1.28 (s)	15.7	1.31 (s)	16.1
1'	4.50 (d, 7.6)	101.4	4.41 (d, 7.6)	101.5	4.40 (d, 7.5)	101.6
2'	3.22 (dd, 9.3, 7.6)	73.9	3.18 (dd, 9.3, 7.6)	73.8	3.17 (dd, 9.0, 7.5)	74.1
3'	3.38 (m)	76.6	3.35 (m)	76.5	3.36 (m)	76.8
4'	3.30 (m)	70.2	3.32 (m)	70.0	3.30 (m)	70.5
5'	3.26 (m)	76.7	3.28 (m)	76.6	3.30 (m)	76.8
6'	3.86 (dd, 12.6, 2.5)	61.3	3.87 (dd, 12.0, 2.5)	61.2	3.84 (dd, 12.2, 2.4)	61.5
	3.68 (dd, 12.6, 5.0)		3.66 (dd, 12.0, 5.0)		3.67 (dd, 12.2, 5.5)	

a) 500 MHz, CD_3OD ; chemical shifts in ppm relative to TMS; coupling constants (J) in Hz.

26.4, 25.8 and 18.7, one methylene carbon at δ_{C} 38.7, two oxygenated methine carbons at δ_{C} 74.3 and 68.6, four olefinic carbons δ_{C} 142.8, 139.9, 133.3 and 131.0 and one quaternary carbon at δ_{C} 36.5. The NMR data were very similar to those of saussureoside B, which was isolated from *Saussurea medusa*.¹¹⁾ The differences were the chemical shifts in ^{13}C -NMR data ($\delta_{\text{C}-1'}$ 101.4, $\delta_{\text{C}-2}$ 38.7, $\delta_{\text{C}-3}$ 74.3, $\delta_{\text{C}-4}$ 68.6 in **1**, $\delta_{\text{C}-1'}$ 106.9, $\delta_{\text{C}-2}$ 43.0, $\delta_{\text{C}-3}$ 66.1, $\delta_{\text{C}-4}$ 84.3 in saussureoside B). The downfield shift at C-3 implied that **1** was glycosylated at C-3.¹¹⁾ The signals from the sugar unit appeared at δ_{H} 4.50 (d, $J=7.6$ Hz), 3.86 (dd, $J=12.6$, 2.5 Hz), 3.68 (dd, $J=12.6$, 5.0 Hz), 3.38, 3.30, 3.26, 3.22 (dd, $J=9.3$, 7.6 Hz) and δ_{C} 101.4, 76.7, 76.6, 73.9, 70.2, 61.3 suggested the presence of D-glucopyranose.¹²⁾ The coupling constant ($J=7.6$ Hz) of the anomeric proton of D-glucose indicated it to be the β -form.¹²⁾ The glycosidic site was established by an heteronuclear multiple bond correlation (HMBC) experiment, in which long-range correlation was observed between the H-3 (δ_{H} 4.01, dt, $J=12.3$, 3.5 Hz) and the C-3 (δ_{C} 74.3) (Fig. 2). The glycosylated proton of H-3 at δ_{H} 4.01 (dt, $J=12.3$, 3.5 Hz) showed couplings in the ^1H - ^1H correlation spectroscopy experiment (COSY) spectrum with H-2 α , H-2 β and H-4. In the HMBC experiment, long-range correlations were observed between the following protons and carbons (H-2, H-11, H-12 and C-1; H-2, H-4, H-1' and C-3; H-4, H-13 and C-5; H-4, H-7, H-11, H-12 and C-6; H-7, H-8, H-10 and C-9). Thus, the structure of **1** was supposed to be 3,4-dihydroxy-5,7-megastigmadien-9-one-3- O - β -D-glucoside. The relative stereochemistry of the aglycone moiety in **1** was characterized by a nuclear Overhauser enhancement spectroscopy (NOESY) experiment, which showed NOE correlations between the following proton pairs (H-2 α and H-3; H-2 β and H-12; H-3 and H-4; H-7 and H-12) as shown in Fig. 2. From the coupling constants at δ_{H} 4.11 (H-4, d, $J=3.5$ Hz), 4.01 (H-3, dt, $J=12.3$, 3.5 Hz), 1.92 (H-2 β , t, $J=12.3$ Hz), 1.64 (H-2 α , dd, $J=12.3$, 3.5 Hz), it is suggested




Fig. 2. ^1H - ^1H COSY, HMBC, and NOESY Correlations of **1**, **2** and **3**

that two hydroxyl groups at C-3 and C-4 are in the *cis* configuration.^{13,14)} Enzymatic hydrolysis of **1** with β -glucosidase (emulsin) yielded 3,4-dihydroxy-5,7-megastigmadien-9-one (**1a**, $\text{C}_{13}\text{H}_{20}\text{O}_3$, $[\alpha]_{\text{D}}^{25} -68^\circ$), whose ^1H -NMR and MS spectra were in good agreement with values reported previously,^{11,15)} and D-glucose $\{[\alpha]_{\text{D}}^{25} +50^\circ$ ($c=0.05$, H_2O)}. The absolute

configuration at C-3 in **1a** was determined by a modified version of Mosher's method.¹⁶⁾ Based on further comparison of the NMR data with those in the literature, the absolute configuration at C-3 in **1** was determined to be the *S*-form.^{11,15)} Thus, the structure of **1** was determined to be (3*S*,4*R*,5*Z*,7*E*)-3,4-dihydroxy-5,7-megastigmadien-9-one-3-*O*- β -D-glucopyranoside, and was named komaroveside A.

Komaroveside B (**2**), was obtained as a colorless gum. The molecular formula of **2** was deduced to be C₁₉H₃₀O₉ by positive mode high resolution electrospray ionization mass spectrometry (HR-ESI-MS) data at *m/z* 425.1781 [M+Na]⁺ (Calcd for C₁₉H₃₀O₉Na: 425.1788). The IR spectrum of **2** showed absorption bands at 3383 and 1658 cm⁻¹ ascribable to a hydroxyl and an unsaturated carbon, respectively. The NMR spectra of **2** were very similar to those of compound **1**. In the ¹³C-NMR spectrum of **2**, two olefinic carbon signals observed at δ_C 139.9 and 131.0 in **1** were shifted upfield to δ_C 70.1 and 68.7 in **2**, which implied that **2** has an epoxide ring instead of the double bond in **1**. These observations suggested the structure of **2** to be 5,6-epoxy-3,4-dihydroxy-7-megastigmen-9-one-3-*O*- β -D-glucoside. The relative stereochemistry of the aglycone in **2** was characterized by a NOESY experiment, which showed NOE correlations between the following proton pairs (H-3 and H-4, 11; H-4 and H-13; H-7 and H-11, 13) as shown in Fig. 2. From the coupling constants at δ_H 4.13 (H-4, d, *J*=3.5 Hz), 3.97 (H-3, dt, *J*=12.5, 3.5 Hz), 1.84 (H-2 β , t, *J*=12.5 Hz), 1.40 (H-2 α , dd, *J*=12.5, 3.5 Hz), it is suggested that two hydroxyl groups at C-3 and C-4 are in the *cis* configuration.^{13,14)} Enzymatic hydrolysis of **2** with β -glucosidase (emulsin) yielded 5,6-epoxy-3,4-dihydroxy-7-megastigmen-9-one (**2a**, C₁₃H₂₀O₃, [α_D^{25} -60.0°), whose ¹H-NMR and MS spectra were in good agreement with values reported previously,^{11,17)} and D-glucose {[α_D^{25} +52° (*c*=0.05, H₂O)}]. The absolute configuration at C-3 of **2a** was determined to be the *S*-form.^{11,15)} by a modified version of Mosher's method.¹⁶⁾ Thus, the structure of **2** was determined to be (3*S*,4*S*,5*S*,6*R*,7*E*)-5,6-epoxy-3,4-dihydroxy-7-megastigmen-9-one-3-*O*- β -D-glucopyranoside, and was named komaroveside B.

Komaroveside C (**3**), was obtained as a colorless gum. molecular formula of **2** was deduced to be C₁₉H₃₄O₁₀ by positive mode high resolution electrospray ionization mass spectrometry (HR-ESI-MS) data at *m/z* 427.1936 [M+Na]⁺ (Calcd for C₁₉H₃₂O₉Na: 427.1944). The IR spectrum of **3** showed an absorption band at 3382 cm⁻¹ ascribable to a hydroxyl function. The NMR spectra of **3** were very similar to those of compound **2**. In the NMR spectra of **3**, the signals at δ_H 4.29 (dq, *J*=6.8, 6.1, 1.0 Hz) and δ_C 67.4 implied that **3** has a hydroxylated function at C-9 instead of the ketone group in **2**. The proton signal at δ_H 4.29 (H-9, dq, *J*=6.8, 6.1, 1.0 Hz) showed coupling in the ¹H-¹H COSY spectrum with H-8 and H-10. Thus, the structure of **3** was supposed to be 5,6-epoxy-3,4,9-trihydroxy-7-megastigmen-3-*O*- β -D-glucoside. The relative stereochemistry of the aglycone in **3** was characterized by a NOESY experiment, which showed NOE correlations between the following proton pairs (H-3 and H-4, 11; H-4 and H-13; H-7 and H-11, 13; H-9 and H-13) as shown in Fig. 2. From the coupling constants at δ_H 4.12 (H-4, d, *J*=3.5 Hz), 3.97 (H-3, dt, *J*=12.8, 3.5 Hz), 1.76 (H-2 β , t, *J*=12.8 Hz), and 1.35 (H-2 α , dd, *J*=12.8, 3.5 Hz), it is suggested that two hydroxyl groups at C-3 and C-4 are in the *cis* configura-




Fig. 3. Results of Hydrolysis and Mosher's Method of **1a**, **2a**, and **3a** Reagents and Conditions

I) β -glucosidase/H₂O, 37°C. II) (*R*)-MTPA and (*S*)-MTPA, EDC·HCl, 4-DMAP/CH₂Cl₂, room temp.

tion.^{13,14)} Enzymatic hydrolysis of **3** with β -glucosidase (emulsin) yielded 5,6-epoxy-3,4,9-trihydroxy-7-megastigmen (**3a**, C₁₃H₂₀O₃, [α_D^{25} -77.0°), whose ¹H-NMR, ¹³C-NMR and MS spectra were very similar to those of 5,6-epoxy-3,4,9-trihydroxy-7-megastigmen, which was isolated from *Staphylea bumalda*,⁹⁾ and D-glucose {[α_D^{25} +51° (*c*=0.05, H₂O)}]. Determination of the absolute configuration at C-3 and C-9 of **3** was done using Mosher's method.¹⁶⁾ Compound **3a**, which was obtained by enzymatic hydrolysis of **3**, was treated with (*S*)-(+), and (*R*)-(-)- α -methoxy- α -trifluoromethylphenyl acetic acid chloride (MTPA-Cl) to give (*R*)- and (*S*)-MTPA esters (**3b**, **c**, respectively). Consequently, the absolute configurations at C-3 and C-9 in **3** were the *S*-form. Thus, the structure of **3** was determined to be (3*S*,4*S*,5*S*,6*R*,7*E*,9*S*)-5,6-epoxy-3,4,9-trihydroxy-7-megastigmen-3-*O*- β -D-glucopyranoside, and was named komaroveside C.

The cytotoxic activities of the isolated compounds (**1**—**11**) were evaluated by determining their inhibitory effects on human tumor cell lines (A549, SK-OV-3, SK-MEL-2, and HCT15) *in vitro* using the sulforhodamine B (SRB) assay.¹⁷⁾ All the compounds showed little cytotoxicity against any tested cell line (IC₅₀>100 μ M).

Experimental

General Experimental Procedures Optical rotations were measured on a Jasco P-1020 polarimeter in MeOH. IR spectra were recorded on a Bruker IFS-66/S FT-IR spectrometer. UV spectra were recorded with a Shimadzu UV-1601 UV-Visible spectrophotometer. ESI and HR-ESI mass spectra were obtained on a IT-TOF (Shimadzu, Japan) mass spectrometer. NMR spectra, including NOESY, COSY, heteronuclear multiple quantum coherence (HMQC) and HMBC experiments, were recorded on a Varian UNITY INOVA 500 NMR spectrometer operating at 500 MHz (¹H) and 125 MHz (¹³C), respectively, with chemical shifts given in ppm (δ). Preparative high-performance liquid chromatography (HPLC) used a Gilson 306 pump with a Shodex refractive index detector. Silica gel 60 (Merck, 70—230 mesh and 230—400 mesh) and RP-C₁₈ silica gel (Merck, 230—400 mesh) were used for column chromatography. Merck pre-coated Silica gel F₂₅₄ plates and RP-18 F₂₅₄ plates were used for TLC. Spots were detected on TLC under UV

light or by heating after spraying with 10% H₂SO₄ in C₂H₅OH (v/v). The packing material for molecular sieve column chromatography was Sephadex LH-20 (Pharmacia Co. U.S.A.). Low pressure liquid chromatography was carried out over a Merck Lichroprep Lobar[®]-A Si 60 (240×10 mm) or a Lichroprep Lobar[®]-A RP-18 (240×10 mm) column with a FMI QSY-0 pump (ISCO).

Plant Materials *Cardamine komarovii* (NAKAI) plants (1.7 kg) were collected at Goseong-gun in Gangwon-Do province, Korea in August 2008. A voucher specimen of the plant (SKK-08-011) was deposited at the School of Pharmacy in Sungkyunkwan University.

Extraction and Isolation The half dried aerial parts of *C. komarovii* (NAKAI) (1.7 kg) were extracted with 80% MeOH three times at room temperature. The resultant MeOH extracts (120 g) were suspended in distilled water (800 ml×3) and then successively partitioned with *n*-hexane, CHCl₃, EtOAc and *n*-BuOH, yielding residues weighing 12 g, 13 g, 3 g and 26 g, respectively. The CHCl₃ soluble fraction (13 g) was chromatographed on a silica gel column, eluting with a gradient solvent system of CHCl₃/MeOH (40:1—1:1) as the eluant to yield seven fraction (fr. PC1—PC7). Fraction PC3 (1.0 g) was isolated by sephadex LH-20 chromatography (80% MeOH) and was purified with a silica gel preparatory HPLC with a solvent system of CHCl₃:MeOH (25:1) to yield **11** (5 mg). The *n*-BuOH soluble fraction (26 g) was chromatographed on a diaion HP-20 column, eluting with a gradient solvent system consisting of 100% water and 100% MeOH. This yielded two subfractions. Fraction B (48 g) was isolated using a silica gel column, eluting with a solvent system of CHCl₃/MeOH/water (10:4:0.5). According to TLC analysis, fourteen crude fractions (fr. PB1—PB14) were collected. Fr. B3 (0.2 g) purified using a Lobar[®]-A RP-18 (240×10 mm) column (40% MeOH), and purified further by preparative reverse-phase HPLC, using a solvent system of 45% MeOH and 25% MeCN, yielded **4** (28 mg) and **8** (14 mg). Fr. B4 (0.5 g) purified by a Lobar[®]-B RP-18 (310×25 mm) column (30% MeOH), and purified further by a preparative reverse-phase HPLC, using a solvent system of 30% MeOH and 20% MeCN, yielded **1** (13 mg), **2** (7 mg) and **5** (19 mg). Fr. PB5 (0.3 g) purified by a Lobar[®]-A RP-18 (240×10 mm) column (35% MeOH), and purified further by preparative reverse-phase HPLC, using a solvent system of 15% MeCN, yielded **6** (5 mg), **7** (10 mg) and **9** (15 mg). Fr. B7 (0.3 g), which was purified by a Lobar[®]-B RP-18 (310×25 mm) column (30% MeOH), and purified further by preparative normal-phase HPLC, using a solvent system of CHCl₃/MeOH (7:1, 3:1) yielded **3** (12 mg) and **10** (9 mg).

Komarovside A (**1**): Colorless gum. [α]_D²⁵ −36.8° (*c*=0.25, MeOH); UV (MeOH) λ _{max} (log ϵ) 227 (4.0), 279 (3.9) nm; IR (KBr) ν _{max} cm^{−1}: 3382, 2924, 1660, 1608, 1425, 1365, 1076; ¹H-NMR (CD₃OD, 500 MHz): see Table 1; ¹³C-NMR (CD₃OD, 125 MHz): see Table 1; HR-ESI-MS (positive mode) *m/z*: 409.1831 [M+Na]⁺ (Calcd for C₁₉H₃₀O₈Na: 409.1838).

Komarovside B (**2**): Colorless gum. [α]_D²⁵ −65.4° (*c*=0.1, MeOH); UV (MeOH) λ _{max} (log ϵ) 229 (4.1) nm; IR (KBr) ν _{max} cm^{−1}: 3383, 2948, 1658, 1450, 1370; ¹H-NMR (CD₃OD, 500 MHz): see Table 1; ¹³C-NMR (CD₃OD, 125 MHz): see Table 1; HR-ESI-MS (positive mode) *m/z*: 425.1781 [M+Na]⁺ (Calcd for C₁₉H₃₀O₈Na: 425.1788).

Komarovside C (**3**): Colorless gum. [α]_D²⁵ −61.4° (*c*=0.1, MeOH); IR (KBr) ν _{max} cm^{−1}: 3382, 2966, 1739, 1627, 1450, 137; positive; ¹H-NMR (CD₃OD, 500 MHz): see Table 1; ¹³C-NMR (CD₃OD, 125 MHz): see Table 1; HR-ESI-MS (positive mode) *m/z*: 427.1936 [M+Na]⁺ (Calcd for C₁₉H₃₀O₈Na: 427.1944).

Enzymatic Hydrolysis of 1, 2 and 3 Compound **1** (3.0 mg) with 1 ml of H₂O and 3 mg of β -glucosidase (Emulsin) was shaken for 7 d at 37 °C. The H₂O solution was then extracted with CHCl₃ three times, and the CHCl₃ extract was evaporated *in vacuo*. The CHCl₃ extract (2.0 mg) was purified using reverse-phase HPLC (50% MeOH) to yield the aglycone **1a** as a colorless gum [α]_D²⁵ −60.5° (*c*=0.1, CHCl₃), ¹H-NMR (pyridine-*d*₅, 500 MHz). Compound **2** (3.0 mg) was treated by the same method. The CHCl₃ extract (2.0 mg) was purified using reverse-phase HPLC (40% MeOH) to yield the aglycone **2a** as a colorless gum [α]_D²⁵ −60.2° (*c*=0.1, CHCl₃), ¹H-NMR (pyridine-*d*₅, 500 MHz). Compound **3** (3.0 mg) was treated by the same method. The CHCl₃ extract (1.0 mg) was purified using reverse-phase HPLC (40% MeOH) to yield the aglycone **3a** as a colorless gum [α]_D²⁵ −77.0° (*c*=0.1, CHCl₃), ¹H-NMR (pyridine-*d*₅, 500 MHz). The sugar in the distilled water layer was identified as *D*-glucose by co-TLC (EtOAc:MeOH:H₂O=9:3:1, *R*_f value: 0.2, **1a**: 1.5 mg, **2a**: 1.5 mg, **3a**: 2.0 mg) with a *D*-glucose standard (Aldrich Co., U.S.A.).

1a: [α]_D²⁵ −60.5° (*c*=0.1, CHCl₃); ¹H-NMR (pyridine-*d*₅, 500 MHz) δ : 7.31 (1H, d, *J*=16.4 Hz, H-7), 6.25 (1H, d, *J*=16.4, H-8), 4.23 (1H, br s, H-4), 4.10 (1H, dt, *J*=12.3, 3.0 Hz, H-3), 2.25 (3H, s, H-10), 2.19 (1H, br t, *J*=12.3 Hz, H-2 β), 1.99 (3H, s, H-13), 1.71 (1H, dd, *J*=12.3, 2.3 Hz, H-2 α),

1.06 (3H, s, H-12), 0.98 (3H, s, H-11); HR-ESI-MS (positive mode) *m/z*: 247.1307 [M+Na]⁺ (Calcd for C₁₃H₂₀O₃Na: 247.1310).

2a: [α]_D²⁵ −60.2° (*c*=0.1, CHCl₃); ¹H-NMR (pyridine-*d*₅, 500 MHz) δ : 7.30 (1H, d, *J*=16.0 Hz, H-7), 6.54 (1H, d, *J*=16.0 Hz, H-8), 4.31 (1H, dt, *J*=12.3, 3.5 Hz, H-3), 2.28 (3H, s, H-10), 2.18 (1H, br t, *J*=12.3 Hz, H-2 β), 1.54 (1H, dd, *J*=12.3, 3.0 Hz, H-2 α), 1.51 (3H, s, H-13), 1.15 (3H, s, H-12), 1.06 (3H, s, H-11); HR-ESI-MS (positive mode) *m/z*: 263.1254 [M+Na]⁺ (Calcd for C₁₃H₂₀O₄Na: 263.1259).

3a: [α]_D²⁵ −77.0° (*c*=0.1, CHCl₃); positive-ion EI-MS *m/z*: 265.15 [M+Na]⁺; ¹H-NMR (CDCl₃, 500 MHz) δ : 5.93 (1H, dd, *J*=15.5, 1.0 Hz, H-7), 5.77 (1H, dd, *J*=15.5, 5.5 Hz, H-8), 4.42 (1H, dqd, *J*=6.5, 5.5, 1.0 Hz, H-9), 4.03 (1H, d, *J*=3.0 Hz, H-4), 3.97 (1H, dt, *J*=12.2, 3.3 Hz, H-3), 1.65 (1H, br t, *J*=12.2 Hz, H-2 β), 1.36 (3H, s, H-13), 1.34 (1H, m, H-2 α), 1.30 (3H, d, *J*=6.5 Hz, H-10), 1.12 (3H, s, H-12), 0.99 (3H, s, H-11); ¹³C-NMR (CDCl₃, 125 MHz) δ : 138.1 (C-8), 124.7 (C-7), 72.1 (C-3), 70.1 (C-6), 68.2 (C-4), 68.0 (C-9), 65.9 (C-5), 39.6 (C-2), 34.2 (C-1), 29.3 (C-11), 24.4 (C-12), 23.7 (C-10), 16.8 (C-13); HR-ESI-MS (positive mode) *m/z*: 265.1412 [M+Na]⁺ (Calcd for C₁₃H₂₂O₄Na: 265.1416).

Preparation of the (R)- and (S)-MTPA-Cl Ester Derivatives of 1a, 2a and 3a by a Convenient Mosher Ester A solution of **1a** (0.7 mg), **2a** (0.7 mg) and **3a** (1.0 mg) in CH₂Cl₂ (1.0 ml) was treated with (*R*)-MTPA (5 μ l) in the presence of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC·HCl, 1.5 mg) and 4-methylaminopyridine (4-DMAP, 0.7 mg), and the mixture was stirred at room temperature for 7 h. After cooling, the reaction mixture was poured into water and the whole reaction mixture was extracted with EtOAc. The EtOAc extract was successively washed with 5% aqueous HCl, saturated aqueous NaHCO₃, and brine, then dried over MgSO₄ powder and filtered. Removal of the solvent from the filtrate under reduced pressure furnished a residue, which was separated by HPLC [MeOH:H₂O=45:55] to give **1b** (0.4 mg), **2b** (0.4 mg) and **3b** (0.5 mg), respectively. Using a similar procedure, (*S*)-MTPA esters **1c** (0.4 mg), **2c** (0.4 mg) and **3c** (0.6 mg) obtained from **1a**, **2a**, and **3a**.

1b: (500 MHz, pyridine-*d*₅) δ : 7.457—7.334 (1H, m, H-7), 6.258 (1H, d, *J*=16.5 Hz, H-8), 5.449 (dt, *J*=12.3, 3.5 Hz, H-3), 4.458 (1H, d, *J*=3.5 Hz, H-4), 2.410 (1H, d, *J*=12.3 Hz, H-2 β), 2.293 (3H, s, H-10), 1.960 (3H, s, H-13), 1.842 (1H, dd, *J*=12.3, 3.5 Hz, H-2 α), 1.139 (3H, s, H-12), 1.023 (3H, s, H-11); HR-ESI-MS (positive mode) *m/z*: 463.1702 [M+Na]⁺ (Calcd for C₂₃H₂₇O₅F₃Na: 463.1708).

1c: (500 MHz, pyridine-*d*₅) δ : 7.420—7.334 (1H, m, H-7), 6.261 (1H, d, *J*=16.5 Hz, H-8), 5.470 (dt, *J*=12.3, 3.5 Hz, H-3), 4.612 (1H, d, *J*=3.5 Hz, H-4), 2.327 (1H, d, *J*=12.3 Hz, H-2 β), 2.303 (3H, s, H-10), 1.993 (3H, s, H-13), 1.717 (1H, dd, *J*=12.3, 3.5 Hz, H-2 α), 1.100 (3H, s, H-12), 0.954 (3H, s, H-11); HR-ESI-MS (positive mode) *m/z*: 463.1689 [M+Na]⁺ (Calcd for C₂₃H₂₇O₅F₃Na: 463.1708).

2b: (500 MHz, pyridine-*d*₅) δ : 7.304 (1H, *J*=16.0 Hz, H-7), 6.556 (1H, d, *J*=16.0 Hz, H-8), 5.705 (dt, *J*=12.3, 3.5 Hz, H-3), 4.547 (1H, d, *J*=3.5 Hz, H-4), 2.439 (1H, d, *J*=12.3 Hz, H-2 β), 2.329 (3H, s, H-10), 1.567 (1H, dd, *J*=12.3, 3.0 Hz, H-2 α), 1.507 (3H, s, H-13), 1.233 (3H, s, H-12), 1.167 (3H, s, H-11) HR-ESI-MS (positive mode) *m/z*: 479.4398 [M+Na]⁺ (Calcd for C₂₃H₂₇O₆F₃Na: 479.4410).

2c: (500 MHz, pyridine-*d*₅) δ : 7.291 (1H, d, *J*=16.0 Hz, H-7), 6.535 (1H, d, *J*=16.0 Hz, H-8), 5.730 (dt, *J*=12.3, 3.5 Hz, H-3), 4.723 (1H, d, *J*=3.5 Hz, H-4), 2.334 (1H, d, *J*=12.3 Hz, H-2 β), 2.311 (3H, s, H-10), 1.565 (1H, dd, *J*=12.3, 3.0 Hz, H-2 α), 1.550 (3H, s, H-13), 1.155 (3H, s, H-12), 1.107 (3H, s, H-11); HR-ESI-MS (positive mode) *m/z*: 479.4401 [M+Na]⁺ (Calcd for C₂₃H₂₇O₆F₃Na: 479.4410).

3b: (500 MHz, pyridine-*d*₅) δ : 6.202 (1H, d, *J*=15.8, H-7), 6.083 (1H, dd, *J*=15.8, 5.5 Hz, H-8), 5.851 (1H, m, H-9), 5.675 (1H, m, H-3), 4.486 (1H, d, *J*=3.5 Hz, H-4), 2.355 (1H, br t, *J*=12.8 Hz, H-2 β), 1.484 (3H, s, H-13), 1.499 (1H, dd, *J*=12.8, 3.5 Hz, H-2 α), 1.391 (3H, d, *J*=6.5 Hz, H-10), 1.118 (3H, s, H-12), 1.089 (3H, s, H-11); HR-ESI-MS (positive mode) *m/z*: 697.2198 [M+Na]⁺ (Calcd for C₃₃H₃₆O₈F₆Na: 697.2212).

3c: (500 MHz, pyridine-*d*₅) δ : 6.287 (1H, d, *J*=15.8, H-7), 6.195 (1H, dd, *J*=15.8, 5.5 Hz, H-8), 5.879 (1H, m, H-9), 5.791 (1H, m, H-3), 4.689 (1H, d, *J*=3.5, H-4), 2.273 (1H, br t, *J*=12.8 Hz, H-2 β), 1.554 (3H, s, H-13), 1.474 (1H, dd, *J*=12.8, 3.5 Hz, H-2 α), 1.265 (3H, d, *J*=6.5 Hz, H-10), 1.125 (3H, s, H-12), 1.069 (3H, s, H-11); HR-ESI-MS (positive mode) *m/z*: 697.2215 [M+Na]⁺ (Calcd for C₃₃H₃₆O₈F₆Na: 697.2212).

Cytotoxicity Assay A sulforhodamin B bioassay (SRB) was used to determine the cytotoxicity of the compounds. The cytotoxic activity of each compound against four cultured human tumor cells was examined *in vitro* at the Korea Research Institute of Chemical Technology. The tumor cell lines were A549 (non small cell lung adenocarcinoma), SK-OV-3 (ovarian cancer cells), SK-MEL-2 (skin melanoma) and HCT15 (colon cancer cells).¹⁷⁾

Doxorubicin was used as the positive control. Regarding the cytotoxicity of doxorubicin, its IC_{50} values for toxicity to A549, SK-OV-3, SK-MEL-2, and HCT15 cells, respectively, were 0.0012, 0.0214, 0.0110 and 0.1322 μM .

Acknowledgments This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (20100029358). We thank Drs. E. J. Bang, S. G. Kim, and J. J. Seo at the Korea Basic Science Institute for their aid in obtaining the NMR and mass spectra.

References

- 1) Lee T. B., "Coloured Flora of Korea," Hyang-Moon Publishing Co., Korea, 2003, p. 433.
- 2) Ahan D. K., "Illustrated Book of Korean Medicinal Herbs," Koy-Hak Publishing Co., Korea, 1998, p. 400.
- 3) Pabst A., Barron D., Semon E., Schreier P., *Phytochemistry*, **31**, 1649—1652 (1992).
- 4) Yamano Y., Ito M., *Chem. Pharm. Bull.*, **53**, 541—546 (2005).
- 5) Kanchanapoom T., Kasai R., Chumsri P., Hiraga Y., Yamasaki K., *Phytochemistry*, **58**, 333—336 (2001).
- 6) Sudo H., Ide T., Otsuka H., Hirata E., Takushi A., Shinzato T., Takeda Y., *Chem. Pharm. Bull.*, **48**, 542—546 (2000).
- 7) Otsuka H., Kamada K., Yao M., Yuasa K., Kida I., Takeda Y., *Phytochemistry*, **38**, 1431—1435 (1995).
- 8) Otsuka H., Hirata E., Shinzato T., Takeda Y., *Phytochemistry*, **62**, 763—768 (2003).
- 9) Yu Q., Matsunami K., Otsuka H., Takeda Y., *Chem. Pharm. Bull.*, **53**, 800—807 (2005).
- 10) Macias F. A., Oliva R. M., Varela R. M., Torres A., Molinillo J. M. G., *Phytochemistry*, **52**, 613—621 (1999).
- 11) Xie H., Wang T., Matsuda H., Morikawa T., Yoshikawa M., Tani T., *Chem. Pharm. Bull.*, **53**, 1416—1422 (2005).
- 12) Perkins S. J., Johnson L. N., Phillips D. C., *Carbohydr. Res.*, **59**, 19—34 (1977).
- 13) Shimizu S., Miyase T., Uedo A., Usmanghani K., *Phytochemistry*, **28**, 3399—3402 (1989).
- 14) Zhang Z., Zhang W., Ji Y. P., Zhao Y., Wang C. G., Hu J. F., *Phytochemistry*, **71**, 693—700 (2010).
- 15) D'Abrosca B., Dellagrega M., Fiorentino A., Isidori M., Monaco P., Pacifico S., *J. Chem. Ecol.*, **32**, 81—96 (2006).
- 16) Ohtani I., Kusumi T., Kashman Y., Kakisawa H., *J. Am. Chem. Soc.*, **113**, 4092—4096 (1991).
- 17) Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R., *J. Natl. Cancer Inst.*, **82**, 1107—1112 (1990).